The addition of itacitinib to standard graft-versus-host-disease prophylaxis may reduce severe toxicities following ...

Fred Hutch’s Phase 2 study among blood cancer patients is a “gamechanger” in preventing graft-versus-host disease after ...

Post-transplant cyclophosphamide (PTCy) plus sirolimus and cyclosporine can improve some outcomes when compared to mycophenolate mofetil (MMF) plus sirolimus and cyclosporine as graft-vs-host disease ...

Hany Elmariah, MD, discussed the safety profile of fedratinib and its evolving role in the post-transplant setting for patients with myeloproliferative neoplasms.

The regulator has cleared Ryoncil (remestemcel-L) to treat steroid-refractory acute GVHD in paediatric patients aged two months and older. It is derived from MSCs harvested from the bone marrow of ...

“Poor nutrition and poor body weight, as well as a loss of muscle mass, can increase the risk of developing GVHD,” says Michelle Bratton, RD, former nutrition educator with the LLS’s ...

For over a thousand people who undergo a stem cell or bone marrow transplant, survival comes at a cost: graft-versus-host disease (GvHD). 1 GvHD is a life-altering condition which affects 30 to 40 per ...